In the past decade, oncologists worldwide have seen unprecedented advances in drug
development and approvals but have also become increasingly cognizant of the rising costs …

Summary This Policy Review sourced opinions from experts in cancer care across low-
income and middle-income countries (LMICs) to build consensus around high-priority …

Background Cancer mortality is high in sub-Saharan Africa (SSA), partly due to inadequate
treatment access. We explored access to and affordability of cancer treatment regimens for …

Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat
or diagnose disease. Nanoparticles (NPs) are a special class of materials at nanometric …

Background: As the first domestic PD-1 antibody approved for lung cancer in China,
camrelizumab has exhibited proven effectiveness for non-small-cell lung cancer (NSCLC) …

Modern phytotherapy is part of today's conventional evidence-based medicine and the use
of phytopharmaceuticals in integrative oncology is becoming increasingly popular …

Background The World Health Organization Model List of Essential Medicines (WHO EML)
has played a critical role in guiding the country-level selection and financing of medicines for …

Abstract Development of resistance to cisplatin, oxaliplatin and carboplatin remains a
challenge for their use as chemotherapies, particularly in breast and colorectal cancer. Here …

Summary Background Resource-stratified guidelines (RSGs) can inform systemic treatment
decisions in the face of limited resources. The objective of this study was to develop a …

Objective: Sugemalimab is approved in China as a first-line treatment in combination with
chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). This study …